Alzamend Neuro Inc. Common Stock (ALZN)
Stock · NASDAQ · Health Care
$1.3as of 10/16/2026
Price chart
Active signals
ALZN Signal Track Record
How signals performed across all stocks →What ALZN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 28 | -6.8% | 39% | October 1, 2026 |
| Volume Spike | 20 | -9.8% | 30% | October 2, 2026 |
| Bollinger Band Breakout | 16 | -6.9% | 19% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -5.6% | 33% | August 31, 2026 |
| Any 20-session window (baseline) | -6.8% | 34% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALZN
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerati…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- alzamend.com/
Fundamentals
- 1-day range
- $1.21$1.48
- Market cap
- $6.61M
- P/E (trailing)
- —
- P/E (forward)
- -1.57
- EPS (trailing)
- $-2.27
- Dividend yield
- —
- Beta
- 0.42
- Avg. volume
- 91.6K
Forecasts
1 analyst ratings
Alzamend Neuro Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALZNAlzamend Neuro Inc. Common Stock$1.3▲ 1.56%Market cap $6.61MP/E —$0.84$2.68
- IMNNImunon Inc. Common Stock$1.02▼ 3.77%Market cap $6.64MP/E —$0.96$5.29
- CVKDCadrenal Therapeutics Inc. Common Stock$1.09▲ 12.37%Market cap $6.67MP/E —$0.8163$14.35
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
- FBLGFibroBiologics Inc. Common Stock$0.971▼ 2.90%Market cap $6.79MP/E —$0.62$9.65
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.1▼ 5.98%Market cap $6.27MP/E —$1.15$7.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.3 | ▲ 1.56% | $0.84$2.68 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.02 | ▼ 3.77% | $0.96$5.29 |
| CVKD Cadrenal Therapeutics Inc. Common Stock | $6.67M | — | $1.09 | ▲ 12.37% | $0.8163$14.35 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
| FBLG FibroBiologics Inc. Common Stock | $6.79M | — | $0.971 | ▼ 2.90% | $0.62$9.65 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.1 | ▼ 5.98% | $1.15$7.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?Yahoo · 9/22/2026
- Alzamend Neuro Regains Compliance with Nasdaq Listing StandardsYahoo · 9/16/2026
- Alzamend Neuro Regains Nasdaq ComplianceBenzinga · 9/16/2026
Insider Activity
Insider Actions →- Milton C. Ault III · August 26, 2026 · Sale2.0K @ $1.56
- Hyperscale Data, Inc. · July 31, 2026 · Grant7.5K @ $1,000
- Milton C. Ault III · July 31, 2026 · Grant7.5K @ $1,000
- Milton C. Ault III · April 14, 2026 · Buy2.0K @ $1.03
- Milton C. Ault III · April 14, 2026 · Buy108.4K @ $1
Institutional Ownership
March 31, 2026
- Total shares held
- 94.5K
- Total value held
- $100.1K
- Institutional holders
- 11
- Unknown45.7K
- Unknown18.0K
- Unknown10.0K
- Unknown6.2K
- Unknown5.2K
- Unknown4.5K
- Unknown4.4K
- Unknown437
- Unknown22
- Unknown4
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Alzamend Neuro (ALZN) Receives Analyst Upgrade
Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.
Alzamend Neuro (ALZN) Receives Analyst Upgrade. Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.